SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 
FORM 6-K

 
Report of Foreign Issuer

PURSUANT to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the Month of October 2007
Commission File Number 0-30860

Axcan Pharma Inc.
(Exact Name of Registrant)

597, boul, Laurier, Mont-Saint-Hilaire (Quèbec), Canada J3H 6C4
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 

 
  Form 20-F
 
  Form 40-F
   
 X

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
 
 
  Yes
 
  No
   
 X



This Form 6-K consists of an October 1, 2007 press release entitled “Axcan Licenses Rights To Cx401, An Innovative Biological Product In Development For The Treatment Of Perianal Fistulas, A Significant Unmet Medical Need”.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
    AXCAN PHARMA INC.
 
  Date: October 2, 2007    By:  /s/ Richard Tarte                                  
    Name:    Richard Tarte
    Title:   Vice President, Corporate Development
      and General Counsel
 
 

 
Axcan Pharma (MM) (NASDAQ:AXCA)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Axcan Pharma (MM) 차트를 더 보려면 여기를 클릭.
Axcan Pharma (MM) (NASDAQ:AXCA)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Axcan Pharma (MM) 차트를 더 보려면 여기를 클릭.